IL217298A0 - 3-cyanoquinoline tablet formulations and uses thereof - Google Patents

3-cyanoquinoline tablet formulations and uses thereof

Info

Publication number
IL217298A0
IL217298A0 IL217298A IL21729811A IL217298A0 IL 217298 A0 IL217298 A0 IL 217298A0 IL 217298 A IL217298 A IL 217298A IL 21729811 A IL21729811 A IL 21729811A IL 217298 A0 IL217298 A0 IL 217298A0
Authority
IL
Israel
Prior art keywords
cyanoquinoline
tablet formulations
formulations
tablet
cyanoquinoline tablet
Prior art date
Application number
IL217298A
Other languages
English (en)
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of IL217298A0 publication Critical patent/IL217298A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL217298A 2009-07-02 2011-12-29 3-cyanoquinoline tablet formulations and uses thereof IL217298A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22253709P 2009-07-02 2009-07-02
PCT/US2010/040555 WO2011002857A2 (fr) 2009-07-02 2010-06-30 Formulations de comprimé de 3- cyanoquinoline et leurs utilisations

Publications (1)

Publication Number Publication Date
IL217298A0 true IL217298A0 (en) 2012-02-29

Family

ID=42732381

Family Applications (1)

Application Number Title Priority Date Filing Date
IL217298A IL217298A0 (en) 2009-07-02 2011-12-29 3-cyanoquinoline tablet formulations and uses thereof

Country Status (15)

Country Link
EP (1) EP2448563A2 (fr)
JP (1) JP2011012063A (fr)
KR (1) KR20120046216A (fr)
CN (1) CN102470109A (fr)
AR (1) AR077546A1 (fr)
AU (1) AU2010266342A1 (fr)
BR (1) BRPI1015941A2 (fr)
CA (1) CA2766067A1 (fr)
IL (1) IL217298A0 (fr)
MX (1) MX2012000048A (fr)
RU (1) RU2011152105A (fr)
SG (1) SG177309A1 (fr)
TW (1) TW201113050A (fr)
WO (1) WO2011002857A2 (fr)
ZA (1) ZA201200366B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102886045A (zh) 2005-02-03 2013-01-23 综合医院公司 治疗吉非替尼耐药性癌症的方法
KR101354828B1 (ko) 2005-11-04 2014-02-18 와이어쓰 엘엘씨 ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP3135285B1 (fr) 2008-06-17 2018-08-15 Wyeth LLC Combinaisons antinéoplasiques contenant du hki-272 et de la vinorelbine
EP2326329B1 (fr) 2008-08-04 2017-01-11 Wyeth LLC Combinaisons antinéoplasiques de 4-anilino-3-cyanoquinoléines et de capécitabine
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft
FI2498756T4 (fi) * 2009-11-09 2023-03-22 Neratinibimaleaatin tablettiformulaatiot
ES2729677T3 (es) 2009-11-09 2019-11-05 Wyeth Llc Esferoides de fármacos recubiertos y sus usos para eliminar o reducir condiciones, como la emesis y la diarrea
CN104447541A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 博舒替尼化合物
CN105384686B (zh) * 2014-09-04 2019-07-26 连云港润众制药有限公司 一种博舒替尼结晶方法
WO2017175855A1 (fr) * 2016-04-08 2017-10-12 Shionogi & Co., Ltd. Forme posologique solide stabilisée
WO2018181574A1 (fr) 2017-03-31 2018-10-04 日精エー・エス・ビー機械株式会社 Contenant en résine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
MY135609A (en) * 2002-02-26 2008-05-30 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
MXPA06001590A (es) 2003-08-19 2006-05-19 Wyeth Corp Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos.
EP1797881B1 (fr) * 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Composition medicamenteuse avec une stabilite amelioree et une tendence de gelification reduite
PL1902029T5 (pl) * 2005-07-01 2022-08-29 Wyeth Llc Krystaliczne postacie 4-[(2,4-dichloro-5-metoksyfenylo)amino]-6-metoksy-7-[3(-4-metylo-1-piperazynylo)propoksy]-3-chinolino-karbonitrylu i sposoby ich wytwarzania
WO2008053295A2 (fr) * 2006-10-30 2008-05-08 Wockhardt Research Centre Compositions pharmaceutiques d'acide benzoquinolizine-2-carboxylique
CN101224185A (zh) * 2007-12-11 2008-07-23 山东蓝金生物工程有限公司 一种治疗实体肿瘤的伯舒替尼缓释植入剂

Also Published As

Publication number Publication date
KR20120046216A (ko) 2012-05-09
ZA201200366B (en) 2012-10-31
CN102470109A (zh) 2012-05-23
WO2011002857A2 (fr) 2011-01-06
WO2011002857A3 (fr) 2011-03-10
TW201113050A (en) 2011-04-16
AU2010266342A1 (en) 2012-01-19
SG177309A1 (en) 2012-02-28
MX2012000048A (es) 2012-01-27
CA2766067A1 (fr) 2011-01-06
EP2448563A2 (fr) 2012-05-09
RU2011152105A (ru) 2013-08-10
BRPI1015941A2 (pt) 2016-04-19
JP2011012063A (ja) 2011-01-20
AR077546A1 (es) 2011-09-07

Similar Documents

Publication Publication Date Title
HRP20181755T1 (hr) Formulacije tableta s trenutnim oslobađanjem
IL253870B (en) Certain amino-pyrimidines and pharmaceutical preparations containing them
ZA201200366B (en) 3-cyanoquinoline tablet formulations and uses thereof
EP2515946A4 (fr) Nanoconjugués et compositions de nanoconjugués
IL214911A0 (en) Solfonylated tetrahydroazolopyrazines and their use as medicinal products
ZA201200722B (en) Pharmaceutical composition and administrations thereof
ZA201108697B (en) Quinoline derivatives-containing pharmaceutical composition
PL2469142T3 (pl) Złączka zaciskowa i jej zastosowanie
HK1169960A1 (en) Pharmaceutical formulation
PT2474522E (pt) Agomelatina e composições farmacêuticas que contêm a mesma
SI2605757T1 (sl) Formulacije na osnovi nalbufina in njihove uporabe
ZA201106702B (en) Sceletium extract and uses thereof
GB0921001D0 (en) Products and uses
ZA201200761B (en) Tablet
ZA201200079B (en) Pharmaceutical compositions and solid forms
AU330360S (en) Tablet
SG10201401678TA (en) Tablet and pestle therefor
GB0920041D0 (en) Tablet
GB0902648D0 (en) Pharmaceutical compounds and compositions
PL2491021T3 (pl) Nowe acylopiperazynony i ich zastosowanie jako środki farmaceutyczne
GB0908317D0 (en) Pharmaceutical compounds and compositions
GB0906703D0 (en) Excipients and their use
GB0903145D0 (en) Medicaments uses and methods
AU331949S (en) Tablet
AU330359S (en) Tablet